The words you are searching are inside this book. To get more targeted content, please make full-text search by clicking here.
Discover the best professional documents and content resources in AnyFlip Document Base.
Published by Oklahoma Medical Research Foundation, 2016-08-22 14:29:27



economic impact2.indd 1 4/6/12 4:28 PM


Each year, OMRF brings more than $30 million to Oklahoma in the
form of competitive research grants from out-of-state sources
such as the National Institutes of Health. Those funds then seed
additional economic activity in the state and create new jobs at
OMRF. These are high-paying, intellectually rewarding positions
with an average compensation level (including fringe benefits) in
excess of $60,000. And each new job at OMRF generates another
additional job in the state. An analysis prepared by a pair of the
state’s leading economists found that OMRF has an annual impact
on Oklahoma’s economy of $46 million and is responsible for more
than 1,000 jobs in the state.

Patents and Spin-Off Companies

The work of OMRF’s scientists has yielded more than 700 domestic
and international patents. These patents speed the movement of
discoveries from the bench to bedside, and each one also represents
a potential new business venture. Currently, OMRF has 27 active
licenses of these patents to biotechnology and pharmaceutical
companies. OMRF’s patents have also formed the basis for 14
different spin-off biotechnology companies, which, in turn, fuel
widespread private-sector growth.


The construction of OMRF’s research tower supported
200 construction jobs in the state. The project had a total
impact of $150 million on Oklahoma’s economy.

economic impact2.indd 2 4/6/12 4:28 PM

Alexion Pharmaceuticals

This Connecticut-based OMRF spin-off created the first and only
treatment for PNH, a blood disorder, and is focused on developing
treatments for other rare conditions. A publicly traded company with
more than 700 employees, Alexion currently has a market capitalization
in excess of $15 billion and is a member of the NASDAQ 100.

Crescendo Bioscience

With offices in San Francisco and Oklahoma
City, Crescendo’s lead product is a blood
test to determine the severity of rheumatoid
arthritis. In 2011, it received $56 million
in Series C funding from a leading venture
capitalist and Myriad Genetics, which also
acquired the right to purchase the company.

CoMentis, Inc.

CoMentis is focused on researching and developing small-molecule
drugs to treat Alzheimer’s disease. The company, which is headquartered
in San Francisco and maintains research operations in Oklahoma City,
has entered into a partnership with Japanese
pharmaceutical giant Astellas that will provide it with
up to $760 million to develop and commercialize
Alzheimer’s drugs.


Eleven other OMRF-based companies are pursuing development
of diagnostics and treatments for a wide range of health
conditions, from hearing loss to breast cancer.

economic impact2.indd 3 4/6/12 4:29 PM

825 NE 13th Street 4/6/12 4:29 PM
Oklahoma City, OK 73104

economic impact2.indd 4

Click to View FlipBook Version